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Molecular imaging is one of the methods to follow-up
stem cell therapy by visualization in the brain. In a
recent article in Stem Cell Research & Therapy, Micci
et al. offer a thorough discussion of the advantages
and disadvantages of this method and their roles in
the future. The authors are among the very first who
have implemented recently introduced molecular
imaging techniques in experimental research and
clinical practice.D2R. As hNIS neither is physiologically expressed inBackground
Current neuroimaging techniques give very limited insight
into molecular and cellular sequences of events. There-
fore, the exact underlying mechanism by which neural
stem cells target physiological or pathological brain areas
remains elusive. Monitoring of these cells is currently also
carried out by the use of various modes of molecular im-
aging, which is a (novel) technology for visualizing metab-
olism and signal transduction to gene expression. Most
importantly, molecular imaging will render possible the
identification of potential therapeutic targets in the devel-
opment of new treatment strategies and in their successful
implementation in clinical application.Discussion
In such a context, Micci et al. [1] have demonstrated
the human sodium iodide symporter (hNIS), a trans-
membrane glycoprotein and widely used probe, as a
new transporter-based reporter gene for non-invasive
molecular imaging and point out one of the principal
challenges of molecular imaging of the brain [2–6].
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applying stem cell transplantation in a clinical medium,
which is necessity for analysis of the benefit to detect,
localize, and examine the stem cells in vivo at both
cellular and molecular levels.
Molecular imaging of stem cells has two principal
advantages over other methods [6–11]: it allows visual
representation, characterization, and quantification of
biological processes in the same live recipient over time
and it is non-invasive. In this context, hNIS may be an
alternative to already-existing vectors like HSV-1 TK or
the brain nor crosses the intact blood–brain barrier, we
can directly examine how it relates to enzymatic activ-
ity or gene expression, being perhaps essential to obtain
a more detailed description of the failure or success of
the cell therapy. Therefore, hNIS incorporated into vec-
tors will make it possible to more fully understand with
a relatively high sensitivity the function of protein net-
works and their role in the spread of stem cells. Such
knowledge will facilitate the discovery of still more in-
formative biomarkers.
This restriction leads us to the question of which vector
probes should be ideal for molecular imaging of cell ther-
apy. Unfortunately, we think that it is easier to answer this
question in different ways. A new vector probe should be
able to help to answer some of the ongoing questions in
stem cell therapy: the most efficacious route of delivery,
the appropriate choice of stem cell type(s), the optimal cell
population for treatment in a chronic setting, and the
favorable time-point of cell delivery. A safe, non-invasive,
and repeatable imaging modality that could identify
injected stem cells would be able to answer questions
about cell viability and retention as well as provide the
ability to adjust the assessment of bioactivity on the
basis of actual delivered doses of cells [7, 8]. In the
long term, stem cell-derived regeneration still faces
difficulties in its efforts to improve because of the
need to monitor stem cells continuously with highis distributed under the terms of the Creative Commons Attribution 4.0
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such circumstances, the properties of differentiation and
self-renewal of stem cells over long periods of time might
be of importance. Moreover, multimodality imaging re-
porter genes will allow us to choose the imaging technolo-
gies that are most appropriate for the biologic problem at
hand and facilitate the clinical application of reporter gene
technologies.
The investigation by Micci et al. [1] is in line with these
current questions of stem cell research, but we have to be
aware that stem cell therapy can be used for the clinical
daily practice only if safety and efficacy of the transplanted
cells can be guaranteed. However, inefficient stem cell
differentiation, difficulty in verifying successful delivery to
the target organ, and problems with engraftment all
hamper the transition from laboratory animal studies to
human clinical trials [7–9]. Therefore, there is a need to
refine and optimize tracking techniques, as is done by
Micci et al. [1]. Moreover, instrumentational improve-
ments, the identification of novel targets and genes, and
imaging probe developments suggest that molecular-
genetic imaging is likely to play an increasingly important
role in the diagnosis and therapy of some brain diseases
[11–14]. Fortunately, the advent of molecular imaging will
continue to lead unprecedented progress in understanding
the fundamental behavior of stem cells, including their
survival, bio-distribution, immunogenicity, and tumoro-
genicity, in the targeted tissues of interest.
Conclusions
Molecular imaging opens a new door to stem cell therapy,
not only in treatment monitoring but also in better under-
standing the underlying (molecular) processes. Tracking
techniques are an important part of this imaging progress
and underline the important impact of molecular imaging
on patient management with stem cell therapy of the brain.
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